ImmuCell Corporation (NASDAQ:ICCC) Sees Large Increase in Short Interest

ImmuCell Corporation (NASDAQ:ICCC) was the recipient of a significant growth in short interest in the month of January. As of January 15th, there was short interest totaling 10,924 shares, a growth of 40.4% from the December 31st total of 7,780 shares. Currently, 0.1% of the company’s stock are short sold. Based on an average daily trading volume, of 27,377 shares, the short-interest ratio is currently 0.4 days. Based on an average daily trading volume, of 27,377 shares, the short-interest ratio is currently 0.4 days. Currently, 0.1% of the company’s stock are short sold.

ImmuCell Price Performance

Shares of NASDAQ:ICCC traded down $0.02 on Friday, hitting $6.02. The stock had a trading volume of 8,934 shares, compared to its average volume of 24,867. The firm’s 50 day moving average price is $5.95 and its 200-day moving average price is $6.10. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.76 and a current ratio of 4.21. ImmuCell has a twelve month low of $4.28 and a twelve month high of $7.60. The company has a market capitalization of $54.48 million, a price-to-earnings ratio of 23.15 and a beta of 0.18.

ImmuCell (NASDAQ:ICCC) last announced its quarterly earnings results on Thursday, November 13th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter. ImmuCell had a net margin of 8.37% and a return on equity of 8.00%. The firm had revenue of $5.51 million for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d+)” rating on shares of ImmuCell in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, ImmuCell has an average rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently raised its position in ImmuCell stock. Geode Capital Management LLC increased its holdings in shares of ImmuCell Corporation (NASDAQ:ICCC) by 4.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 71,852 shares of the biotechnology company’s stock after purchasing an additional 2,907 shares during the period. Geode Capital Management LLC owned approximately 0.79% of ImmuCell worth $500,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 13.47% of the company’s stock.

About ImmuCell

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.